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OBJECTIVE— To study the association between peri-conceptional A1C and serious adverse
pregnancy outcome (congenital malformations and perinatal mortality).
RESEARCH DESIGN ANDMETHODS— Prospective data were collected in 933 sin-
gleton pregnancies complicated by type 1 diabetes.
RESULTS— The risk of serious adverse outcome at different A1C levels was compared with
the background population. The risk was significantly higher when peri-conceptional A1C
exceeded 6.9%, and the risk tended to increase gradually with increasing A1C. Women with A1C
exceeding 10.4% had a very high risk of 16%. Congenital malformation rate increased signifi-
cantly at A1C above 10.4%, whereas perinatal mortality was increased even at A1C below 6.9%.
CONCLUSIONS— These results support recent guidelines of preconceptional A1C levels
7% in women with type 1 diabetes.
Diabetes Care 32:1046–1048, 2009
R ecently, guidelines for managementof pregnancy in women with pre-gestational diabetes have recom-
mended pregestational A1C values
7.0% (1,2) and 6.1% (3). Previous
studies have reported information of early
A1C including 116–691 pregnancies (4–
10). We aimed to study whether there is a
threshold value for peri-conceptional
A1C in women with type 1 diabetes below
which the risk of serious adverse preg-
nancy outcome (congenital malformation
and perinatal mortality) is not increased.
RESEARCH DESIGN AND
METHODS— During 1993–1999,
pregnancies in women with type 1 diabe-
tes were prospectively reported from
eight centers to a central registry in the
Danish Diabetes Association (11). Evalu-
ated by alternative local data sources, the
coverage was 75–93% and clinical data
showed no differential selection. Stan-
dard guidelines included prepregnancy
counseling, but only 58% attended this
(11). A dose of 400 g folic acid was rec-
ommended in early pregnancy. All pa-
tients gave informed consent, and the
local ethics committees approved the
study.
Inclusion criteria were as follows: de-
livery after 24 completed weeks (n 
1,215) or termination before 24 weeks
because of ultrasound-verified malforma-
tions (n  3). Multiple and recurrent
pregnancies were excluded, leaving 933
pregnancies. Of these, 784 had complete
data on preconceptional A1C, whereas
first-trimester A1C was used as a surro-
gate in 149 cases. Background population
data were based on 70,089 deliveries re-
corded by the Danish Health Board in
1995 (11).
Four different local A1C assays were
prospectively subjected to centralized
quality control: Mono-S HPLC method,
Boehringer Mannheim Tinaquant, Roche
Unimate, and Abbott IMx. A standard as-
say (Mono-S) based on nonpregnant sub-
jects (5.4  1.0% [mean  2 SD]) was
used for reference. Correction was made
in50% by multiplying A1C with a cor-
rection factor (mean of reference values
for the standard assay divided by mean of
the reference values for the given assay).
The z scores were derived from the stan-
dard assay. Corresponding z scores and
A1C values are shown in Table 1.
Perinatal mortality was intrauterine
death at 24 weeks or death during the
first 7 days of life. Major congenital mal-
formations were those responsible for
death, causing a significant future handi-
cap or requiring major surgery, while mi-
nor congenital malformations comprised
the remainder (8). Congenital malforma-
tions were assessed during hospital stay.
Data were analyzed by STATA 9.0
(Stata Corporation) and are given as per-
cent or relative risk and 95% CIs. The 2
test was used for comparing outcomes at
different A1C levels.
RESULTS— Participants were 28.6
4.8 years old with a prepregnancy BMI of
23.6  3.5 kg/m2; duration of diabetes
was 12.3 7.9 years, and time for admis-
sion was 9.6 3.5 weeks (means SD).
All women were Caucasian. A total of 71
infants had serious adverse outcome: 45
congenital malformations (including 23
major) and 31 perinatal deaths (5 with
major malformations).
The relative risks of serious adverse
outcome at increasing levels of peri-
conceptional A1C compared to the back-
ground population are presented in Table
1. The risk was increased when A1C ex-
ceeded 6.9% and tended to increase grad-
ually with increasing A1C. Congenital
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malformation rate increased significantly
at A1C above 10.4%, whereas perinatal
mortality was increased even at an A1C
below 6.9%.
CONCLUSIONS— To our knowl-
edge, the present study is the largest pro-
spective population-based study in
pregnant women with type 1 diabetes
with information of peri-conceptional
A1C. Denmark is a small country with an
overall consensus on prenatal care, and
with the central validation of the A1C
analysis, we find our results representa-
tive and valid.
We used a reference based on A1C
values outside pregnancy, and although
A1C has been shown to decline during
pregnancy (12), this is not until later
stages of gestation.
The 3.9% risk of infants with congen-
ital malformations in diabetic women
with A1C z scores3 (A1C 6.9%) did not
differ significantly from the 2.8% back-
ground population risk. This can be due
to a true biologic relationship but could
also be explained by lack of power (only
21%), since the study was not designed to
specifically address this association. It is
therefore still possible that no safe A1C
threshold exists above the upper normal
range. The risk of congenital malforma-
tion at A1C z scores above 10 (A1C
10.4%) was fourfold and significantly in-
creased compared with the background
population. Perinatal mortality was in-
creased also when z score was 3, most
likely reflecting the well-known fact that
factors other than hyperglycemia, such as
smoking, nephropathy, preeclampsia,
preterm delivery, and A1C in late preg-
nancy, affect perinatal mortality.
Suhonen et al. (9) studied 709 off-
spring of type 1 diabetic women and
found an increased risk of congenital mal-
formations at slightly raised A1C values (z
scores of 2.0–5.9). Analyzing 573 type 1
diabetic pregnancies, Nielsen et al. (5) re-
ported a dose-dependent association be-
tween the risk for adverse pregnancy
outcome (abortion, stillbirth, neonatal
death, or major congenital malformation)
and first trimester A1C without any
threshold value. Hanson et al. (7) exam-
ined 532 women with type 1 diabetes and
222 control subjects, demonstrating a sig-
nificant increase in congenital malforma-
tion and spontaneous abortion at A1C z
scores 8.
The risk of the composite serious ad-
verse outcome among diabetic women in
our study was higher than in the back-
ground population when peri-concep-
tional A1C z scores exceeded three, but
again, it cannot be ruled out that the risk
at A1C z scores3 would have been sig-
nificantly increased in a larger study. As
illustrated in Table 1, the risk of serious
adverse outcome increased abruptly at
A1C z score 10, suggesting three levels
of risk: z score3 (low risk); z score 3–10
(intermediate risk), and z score 10
(high risk). Women attending prepreg-
nancy care have significantly lower A1C
levels than nonattenders (13), indicating
that improved prepregnancy glycemic
control is the target for reducing the risk
of serious adverse diabetic pregnancy out-
comes. The experience of many clinicians
dealing with planning of pregnancy in
women with type 1 diabetes is that A1C z
score 3 is often obtainable and associ-
ated with a limited number of mild hypo-
glycemic episodes.
In conclusion, the results of this study
support a recommendation of preconcep-
tional A1C levels 7% in women with
type 1 diabetes, emphasizing the impor-
tance of prepregnancy counseling.
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